概括
对冲击的多巴胺化物治疗表明,治疗前的动脉乳酸盐水平,而不是循环缺陷的严重程度,预测了生存率. 在多巴胺治疗期间改善脚温度也表明了积极的结果.
科学领域:
- 心脏病学 心脏病学
- 临界护理医学 临界护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环休克是一种危及生命的疾病,表现为周围和代谢障碍.
- 多巴胺化是一种用于控制冲击的血管压缩剂.
- 休克患者的生存预测因素仍然是关键研究领域.
研究的目的:
- 为了研究多巴胺化对与冲击有关的缺陷的治疗作用.
- 为了确定循环休克患者的生存的可靠指标.
主要方法:
- 一项涉及34名患有循环休克 (心肌梗塞,细菌病,低血压) 的患者的研究.
- 在多巴胺化物治疗前和治疗期间评估循环参数 (低血压,心脏输出,寡尿症,脚温度) 和动脉乳酸盐水平.
主要成果:
- 循环系统缺陷的治疗前严重程度与生存率没有相关性.
- 治疗前动脉乳酸度是生存的重要预测指标;正常或轻微升高的水平表明生存的可能性更高.
- 治疗前动脉乳酸盐水平大幅增加的患者没有生存,无论多巴胺治疗如何.
- 在多巴胺治疗期间脚温度升高是一个强烈的积极预后指标.
结论:
- 在服用多巴胺化之前的动脉乳酸盐水平对于预测休克患者的生存至关重要.
- 在多巴胺治疗期间监测脚温度变化可以提供对患者预后的见解.
- 多巴胺酸的疗效受到潜在的代谢状态的影响,特别是乳酸水平,在休克状态下.
相关概念视频
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Blood Pressure Imbalances and Circulatory Shock
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


